You are here

Pharmadrug Inc.

Listing Exchange: 
CSE
Status: 
Active
Industry: 
Life Sciences
Symbol: 
PHRX
CSE Index: 
Currency: 

PharmaDrug is a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs. PharmaDrug owns 100% of Pharmadrug Production GmbH (“Pharmadrug Production”), a German medical cannabis distributor, with a Schedule I European Union narcotics license and German EuGMP certification allowing for the importation and distribution of medical cannabis to pharmacies in Germany and throughout the European Union. PharmaDrug owns 100% Sairiyo Therapeutics (“Sairiyo”), a biotech company that specializes in researching and reformulating established natural medicines with a goal of bringing them through clinical trials and the associated regulatory approval process in the US and Europe. Sairiyo is currently developing its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious disease and rare cancers. Sairiyo is also conducting R&D in the psychedelics space for the treatment of non-neuropsychiatric conditions. The Company also owns 100% of Super Smart, a company building a vertically integrated retail business with the goal to elevate the use of functional mushrooms as natural based medicines.

Pharmadrug Inc. (PHRX)

Company Info

Address
77 King St. West, Suite 2905
Toronto, ON M5K 1H1
Canada
Phone
647-202-1824
Fax
416-765-0029
Email
info@aurahealthinc.com
Website
http://www.pharmadrug.com
Listing date
Thursday, August 16, 2018
Transfer Agent
Capital Transfer Agency

SEDAR Information

Company Info

Address
77 King St. West, Suite 2905
Toronto, ON M5K 1H1
Canada
Phone
647-202-1824
Fax
416-765-0029
Email
info@aurahealthinc.com
Website
http://www.pharmadrug.com
Listing date
Thursday, August 16, 2018
Transfer Agent
Capital Transfer Agency

Capitalization

Issued & Outstanding: 
104556647
Reserved for Issuance: 
15240323

Company Officers

Robert Steen, CEO
Kyle Appleby, CFO